🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Exclusive: South Korea set to ship coronavirus testing kits to U.S. - source

Published 2020-04-13, 03:01 a/m
© Reuters. FILE PHOTO: A medical staff member in protective gear prepares to take samples from a visitor at a 'drive-thru' testing center for the novel coronavirus disease of COVID-19 in Yeungnam University Medical Center in Daegu

By Hyonhee Shin and Sangmi Cha

SEOUL (Reuters) - South Korea plans to send kits designed to run up to 600,000 coronavirus tests to the United States on Tuesday after an appeal from U.S. President Donald Trump, a Seoul official said.

Trump made the request in a telephone call with President Moon Jae-in on March 25, as the United States was grappling with fast-growing outbreaks in many states.

South Korean companies have previously shipped test kits to U.S. cities including Los Angeles, but this would mark the first bulk order from the U.S. federal government.

A U.S. Federal Emergency Management Agency cargo plane carrying the equipment is scheduled to leave at 10:30 p.m. (1330 GMT) on Tuesday, the official said on Monday, speaking on condition of anonymity due to the sensitivity of the issue.

South Korea's foreign minister Kang Kyung-wha confirmed the Reuters report in an interview on French news channel France 24, saying that contracts have been signed and the shipments will be "ready any time soon".

The first shipments will be handed over to and paid for by the U.S. government, the official told Reuters.

An additional package of kits that can conduct as many as 150,000 tests will be exported in the near future and will be sold through an unspecified local retailer, the official said.

The polymerase chain reaction (PCR) kits will be sourced from three companies that secured preliminary approval late last month from the U.S. Food and Drug Administration (FDA) to export kits to the United States, the official said.

He declined to name the two companies that will provide the shipments on Tuesday.

However, a person with direct knowledge of the matter said, on condition of anonymity, that one of the two firms is Osang Healthcare and the company will provide kits for 300,000 tests.

Calls to Osang Healthcare for a comment were not answered.

Once struggling with the first large outbreak outside China, South Korea has largely managed to bring its coronavirus cases under control without major disruptions thanks to a massive testing campaign and intensive contact tracing.

South Korea credits part of its success to moves by government officials and private companies to develop and secure regulatory approval for tests, allowing the country to quickly test thousands of people.

The United States has recorded more fatalities from COVID-19, the respiratory disease caused by the coronavirus, than any other country, nearly 22,000 as of Sunday, with 42 states imposing strict stay-at-home orders.

© Reuters. FILE PHOTO: A medical staff member in protective gear prepares to take samples from a visitor at a 'drive-thru' testing center for the novel coronavirus disease of COVID-19 in Yeungnam University Medical Center in Daegu

"We've moved as quickly as possible to get necessary clearances given the urgency of the situation there," the South Korean official said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.